Bartlomiej Przychodzen
Vanda Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Cancer Genomics and Diagnostics, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms(2015)430 cited
- → STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia(2012)410 cited
- → Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis(2012)369 cited
- → Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation(2017)344 cited
- → Somatic SETBP1 mutations in myeloid malignancies(2013)266 cited
- → Genetic alterations of the cohesin complex genes in myeloid malignancies(2014)262 cited
- → Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value(2010)219 cited
- → AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia(2017)188 cited
- → STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients(2013)159 cited
- → Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms(2013)156 cited